Molly M. Gilligan

Molly M. Gilligan

Auto-generated profile, based on publicly available information

Molly M. Gilligan

Department of Medicine, Division of Hematology/Oncology, Weill Cornell Medicine/NewYork Presbyterian Hospital

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2017 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
MSMegan L. Sulciner
Megan L. Sulciner
CSCharles Serhan
Charles Serhan
MGMolly M. Gilligan
Molly M. Gilligan
DMDayna K. Mudge
Dayna K. Mudge
JCJaimie Chang
Jaimie Chang
DPDipak Panigrahy
Dipak Panigrahy
Cancer therapy reduces tumor burden by killing tumor cells, yet it simultaneously creates tumor cell debris that may stimulate inflammation and tumor growth. Thus, conventional cancer therapy is inherently a double-edged sword. In this study, we show that tumor cells killed by chemotherapy or targeted therapy (“tumor cell debris”) stimulate primary tumor growth when coinjected with a subthreshold (nontumorigenic) inoculum of tumor cells by triggering macrophage proinflammatory cytokine release after phosphatidylserine exposure. Debris-stimulated tumors were inhibited by antiinflammatory and proresolving lipid autacoids, namely resolvin D1 (RvD1), RvD2, or RvE1. These mediators specifically inhibit debris-stimulated cancer progression by enhancing clearance of debris via macrophage phagocytosis in multiple tumor types. Resolvins counterregulate the release of cytokines/chemokines, including TNFα, IL-6, IL-8, CCL4, and CCL5, by human macrophages stimulated with cell debris. These results demonstrate that enhancing endogenous clearance of tumor cell debris is a new therapeutic target that may complement cytotoxic cancer therapies.

1 September 2020 in The American Journal of Pathology
Verified
Journal Article
Closed access
BHBruce Hammock
Bruce Hammock
WWWeicang Wang
Weicang Wang
MGMolly M. Gilligan
Molly M. Gilligan
DPDipak Panigrahy
Dipak Panigrahy

8 February 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
AKAbigail G. Kelly
Abigail G. Kelly
WWWeicang Wang
Weicang Wang
EREva Rothenberger
Eva Rothenberger
JYJun Yang
Jun Yang
MGMolly M. Gilligan
Molly M. Gilligan
DPDipak Panigrahy
Dipak Panigrahy
Cancer therapy, including immunotherapy, is inherently limited by chronic inflammation-induced tumorigenesis and toxicity within the tumor microenvironment. Thus, stimulating the resolution of inflammation may enhance immunotherapy and improve the toxicity of immune checkpoint inhibition (ICI). As epoxy-fatty acids (EpFAs) are degraded by the enzyme soluble epoxide hydrolase (sEH), the inhibition of sEH increases endogenous EpFA levels to promote the resolution of cancer-associated inflammation. Here, we demonstrate that systemic treatment with ICI induces sEH expression in multiple murine cancer models. Dietary omega-3 polyunsaturated fatty acid supplementation and pharmacologic sEH inhibition, both alone and in combination, significantly enhance anti-tumor activity of ICI in these models. Notably, pharmacological abrogation of the sEH pathway alone or in combination with ICI counter-regulates an ICI-induced pro-inflammatory and pro-tumorigenic cytokine storm. Thus, modulating endogenous EpFA levels through dietary supplementation or sEH inhibition may represent a unique strategy to enhance the anti-tumor activity of paradigm cancer therapies.

1 December 2020 in Pediatric Diabetes
Verified
Journal Article
Closed access
PDF file
MGMolly M. Gilligan
Molly M. Gilligan
JLJacqueline C. Linnes
Jacqueline C. Linnes
JOJulia E Oettingen
Julia E Oettingen
KAKetly Altenor
Ketly Altenor